Published in ACS Nano on September 25, 2012
Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J Nanobiotechnology (2013) 1.57
Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano (2013) 1.47
Nanoparticle-cell interactions: molecular structure of the protein corona and cellular outcomes. Acc Chem Res (2014) 0.99
Protein binding modulates the cellular uptake of silver nanoparticles into human cells: implications for in vitro to in vivo extrapolations? Toxicol Lett (2013) 0.94
Adsorption of a Protein Monolayer via Hydrophobic Interactions Prevents Nanoparticle Aggregation under Harsh Environmental Conditions. ACS Sustain Chem Eng (2013) 0.93
Interaction of colloidal nanoparticles with their local environment: the (ionic) nanoenvironment around nanoparticles is different from bulk and determines the physico-chemical properties of the nanoparticles. J R Soc Interface (2014) 0.91
The nano-plasma interface: Implications of the protein corona. Colloids Surf B Biointerfaces (2014) 0.90
Current understanding of interactions between nanoparticles and the immune system. Toxicol Appl Pharmacol (2015) 0.82
Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles. Nanomedicine (2014) 0.81
Value of phagocyte function screening for immunotoxicity of nanoparticles in vivo. Int J Nanomedicine (2015) 0.78
Adsorption and Unfolding of a Single Protein Triggers Nanoparticle Aggregation. ACS Nano (2016) 0.78
Surfactant protein A (SP-A) inhibits agglomeration and macrophage uptake of toxic amine modified nanoparticles. Nanotoxicology (2015) 0.76
Size and surface modification of amorphous silica particles determine their effects on the activity of human CYP3A4 in vitro. Nanoscale Res Lett (2014) 0.76
Interaction of gold nanoparticles with proteins and cells. Sci Technol Adv Mater (2015) 0.75
Protein corona: a new approach for nanomedicine design. Int J Nanomedicine (2017) 0.75
Serum protein adsorption and excretion pathways of metal nanoparticles. Nanomedicine (Lond) (2015) 0.75
The nanoparticle protein corona formed in human blood or human blood fractions. PLoS One (2017) 0.75
The Role of Controlled Surface Topography and Chemistry on Mouse Embryonic Stem Cell Attachment, Growth and Self-Renewal. Materials (Basel) (2017) 0.75
Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol (2010) 2.00
A new principle for tight junction modulation based on occludin peptides. Mol Pharmacol (2003) 1.88
Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology (2009) 1.43
Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med (2012) 1.41
Immunophilin chaperones in steroid receptor signalling. Curr Top Med Chem (2003) 1.41
Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg Med Chem (2006) 1.23
Modern subunit vaccines: development, components, and research opportunities. ChemMedChem (2013) 1.22
Ultrafast synthesis of ultrahigh molar mass polymers by metal-catalyzed living radical polymerization of acrylates, methacrylates, and vinyl chloride mediated by SET at 25 degrees C. J Am Chem Soc (2006) 1.18
Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis (2007) 1.16
Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J Biol Chem (2004) 1.15
Self-adjuvanting lipopeptide vaccines. Curr Med Chem (2008) 1.10
Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother (2013) 1.10
Contact lens sensors in ocular diagnostics. Adv Healthc Mater (2014) 1.08
Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol (2003) 1.06
Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr Drug Deliv (2006) 1.01
Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev (2011) 1.00
Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun (2010) 0.98
Cellular uptake of densely packed polymer coatings on gold nanoparticles. ACS Nano (2010) 0.98
Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. ACS Nano (2014) 0.97
Plasma protein binding of positively and negatively charged polymer-coated gold nanoparticles elicits different biological responses. Nanotoxicology (2012) 0.94
Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew Chem Int Ed Engl (2010) 0.94
Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. J Med Chem (2007) 0.94
Exocytosis of nanoparticles from cells: role in cellular retention and toxicity. Adv Colloid Interface Sci (2013) 0.94
Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharm Res (2008) 0.94
Polyamine-dependent regulation of spermidine-spermine N1-acetyltransferase mRNA translation. J Biol Chem (2007) 0.93
Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res (2007) 0.92
Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. Bioorg Med Chem (2008) 0.92
Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res (2012) 0.92
Arylamine N-acetyltransferase 1 gene regulation by androgens requires a conserved heat shock element for heat shock factor-1. Carcinogenesis (2010) 0.91
Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr Drug Deliv (2005) 0.91
Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics (2008) 0.91
Interaction of the Hsp90 cochaperone cyclophilin 40 with Hsc70. Cell Stress Chaperones (2004) 0.91
Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities. Biochem J (2005) 0.90
RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One (2011) 0.90
Cellular uptake of self-assembled cationic peptide-DNA complexes: multifunctional role of the enhancer chloroquine. J Control Release (2009) 0.90
Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. J Infect Dis (2006) 0.89
Specific modulation of airway epithelial tight junctions by apical application of an occludin peptide. Mol Pharmacol (2005) 0.89
An influenza virus-inspired polymer system for the timed release of siRNA. Nat Commun (2013) 0.88
Reusable, robust, and accurate laser-generated photonic nanosensor. Nano Lett (2014) 0.87
Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res (2004) 0.87
Chemical methods for peptide and protein production. Molecules (2013) 0.87
Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship. PLoS One (2012) 0.87
A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun (2002) 0.87
Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships. Front Immunol (2013) 0.86
In vitro permeability and metabolic stability of bile pigments and the effects of hydrophilic and lipophilic modification of biliverdin. Bioorg Med Chem (2008) 0.85
Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J Med Chem (2012) 0.85
Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun (2003) 0.85
Peptide-based subunit nanovaccines. Curr Drug Deliv (2011) 0.84
Interaction of densely polymer-coated gold nanoparticles with epithelial Caco-2 monolayers. Biomacromolecules (2011) 0.84
Toll-like receptor agonists: a patent review (2011 - 2013). Expert Opin Ther Pat (2014) 0.84
Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation. Int J Pharm (2005) 0.84
Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem (2008) 0.83
Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand. J Med Chem (2012) 0.83
Enhanced transdermal peptide delivery and stability by lipid conjugation: epidermal permeation, stereoselectivity and mechanistic insights. Pharm Res (2014) 0.83
Regulation of arylamine N-acetyltransferases. Curr Drug Metab (2008) 0.83
Comparison of the in vitro apparent permeability and stability of opioid mimetic compounds with that of the native peptide. Bioorg Med Chem Lett (2007) 0.83
Identification of a minimal promoter sequence for the human N-acetyltransferase Type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1). Biochem J (2003) 0.83
5-methyl-tetrahydrofolate and the S-adenosylmethionine cycle in C57BL/6J mouse tissues: gender differences and effects of arylamine N-acetyltransferase-1 deletion. PLoS One (2013) 0.83
Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery. Methods Mol Biol (2011) 0.83
Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components. J Med Chem (2010) 0.83
Oral vaccine delivery--new strategies and technologies. Curr Drug Deliv (2009) 0.82
Facile fabrication of core-shell-structured Ag@carbon and mesoporous yolk-shell-structured Ag@carbon@silica by an extended Stöber method. Chemistry (2013) 0.82
Peptide-based subunit vaccine against hookworm infection. PLoS One (2012) 0.82
Simple synthetic toll-like receptor 2 ligands. Bioorg Med Chem Lett (2011) 0.82
Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin. Bioorg Med Chem (2005) 0.82
Design, synthesis, and evaluation of a liposaccharide drug delivery agent: application to the gastrointestinal absorption of gentamicin. J Med Chem (2004) 0.82
Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. Biomacromolecules (2013) 0.82
Peptide conjugation via CuAAC 'click' chemistry. Molecules (2013) 0.82
Lipophilic derivatives of leu-enkephalinamide: in vitro permeability, stability and in vivo nasal delivery. Bioorg Med Chem (2010) 0.82
Biological properties and therapeutic potential of bilirubin. Mini Rev Med Chem (2003) 0.81
Advances in peptide-based human papillomavirus therapeutic vaccines. Curr Top Med Chem (2012) 0.81
Multifunctional nanoworms and nanorods through a one-step aqueous dispersion polymerization. J Am Chem Soc (2014) 0.81
Novel cationic lipophilic peptides for oligodeoxynucleotide delivery. Bioorg Med Chem (2007) 0.81
Synthesis, structure elucidation, in vitro biological activity, toxicity, and Caco-2 cell permeability of lipophilic analogues of alpha-conotoxin MII. J Med Chem (2003) 0.81
Thermoresponsive worms for expansion and release of human embryonic stem cells. Biomacromolecules (2014) 0.81
Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2. Vaccine (2009) 0.81
Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol (2002) 0.81
Expression of maturation markers on murine dendritic cells in response to group A streptococcal lipopeptide vaccines. Vaccine (2009) 0.81
Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem (2006) 0.80
Enhancement of drug affinity for cell membranes by conjugation with lipoamino acids II. Experimental and computational evidence using biomembrane models. Int J Pharm (2006) 0.80
Determination of transport in the Caco-2 cell assay of compounds varying in lipophilicity using LC-MS: enhanced transport of Leu-enkephalin analogues. Eur J Pharm Sci (2002) 0.80
Oral absorption and in vivo biodistribution of alpha-conotoxin MII and a lipidic analogue. Biochem Biophys Res Commun (2007) 0.80
Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine (Lond) (2012) 0.80
Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine. Nanomedicine (Lond) (2013) 0.80
Laser engineered graphene paper for mass spectrometry imaging. Sci Rep (2013) 0.80
Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products. Med Res Rev (2009) 0.80